Cell Growth pp 773-798 | Cite as

Cell Kinetics in Clinical Oncology

  • Barthel Barlogie
  • Benjamin Drewinko
  • Martin N. Raber
  • Douglas E. Swartzendruber
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 38)


While the etiology of most human cancers is still unknown and may be multifactorial, a number of epiphenomena discriminating normal from malignant cells have been discovered, including genetic (1, 2), biochemical (3, 4, 5), and cytokinetic parameters (6, 7). Focusing on the kinetics of tumor growth in this chapter, we will: (1) delineate how measurements of cell kinetics parameters can serve as quantitative descriptors of malignant disease potentially determining response to cytotoxic therapy; (2) review strategies to either differentially enhance tumor cell kill or to establish a viable symbiosis between tumor and host via tumor cell differentiation; and (3) address the feasibility of cytokinetic methods to predict drug responsiveness in vitro and in vivo.


Labelling Index Acute Leukemia Acridine Orange Cell Kinetics Tritiated Thymidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. C. Nowell, “Chromosomes changes and the clonal evolution of cancer” in: Chromosomes in Cancer, edited by J. German, New York, Wiley and Sons, (1974).Google Scholar
  2. 2.
    J. D. Rowley and D. Potter “Chromosomal banding patterns in acute non-lymphocytic leukemia” Blood, 47: 705–721 (1976).PubMedGoogle Scholar
  3. 3.
    R. Baserga, “Biochemical, molecular and pharmacologic Approaches to large bowel cancer. An Overview” Cancer, 45: 1168–1171 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    H. Busch, N. R. Ballel, R. K. Busch, Y. C. Choi, F. Davis, I. L. Goldknopf, S. I. Matsui, M.S. Rao and L. I. Hoffbloom, “The nucleolus. A model for analysis of chromatin controls” Cold Spring Harbor Symposium, Vol. 42 (1978).Google Scholar
  5. 5.
    H. Busch, F. Gyorkey, R. K. Busch, F. M. David, P. Yorke and A. K. Smetana, “A nucleolar antigen found in a broad range of tumor specimens” Cancer Res. 39: 3024–3030 (1979).PubMedGoogle Scholar
  6. 6.
    G. G. Steel, Growth kinetics of tumors; cell population kinetics in relation to the growth and treatment of cancer, Clarendon Press, Oxford (1977).Google Scholar
  7. 7.
    R. Baserga, The cell cycle and cancer, Marcel Dekker, Inc., New York (1971).Google Scholar
  8. 8.
    F. M. Schabel, Jr., D. P. Griswold, Jr., T. H. Corbett, W. R. Laster, Jr., J. G. Mayo and H. H. Lloyd “Testing therapeutic hypothesis in mice and man: observation on the therapeutics activity against advanced solid tumor of mice treated with anticancer drugs that have demonstrated potential clinical utility for treatment of advanced solid tumor in man” In: Cancer Drug Development-Methods in Cancer Research, edited by H. Busch and V. De Vita, Jr., Vol. 17, New York Academic Press, Inc. (1979).Google Scholar
  9. 9.
    R. B. Livington and J. S. Hart “The clinical application of cell kinetics in cancer therapy” Ann. Rev. Pharmacol. Toxicol. 71: 529–543 (1977).CrossRefGoogle Scholar
  10. 10.
    E. A. Gehan, T. O. Smith, E. J. Freireich, G. Body, V. Rodriguez, J. Speer and K. McCredie “Prognostic factors in acute leukemia” Seminars in Oncology, 3: 271–281 (1976).PubMedGoogle Scholar
  11. 11.
    V. T. De Vita, “PH: Changing Concepts: the lymphomas” in: Adjuvant Therapy of Cancer II, edited by S. E. Jones and S. E. Salmon, Grune and Stratton (1979).Google Scholar
  12. 12.
    R. Alexanian and B. Drewinko, “Multiple myeloma and related plasma syndromes” in: Cancer patient care at M.D. Anderson Hospital and Tumor Institute, edited by R. L. Clark and C. D. Howe, Year Book Medical Publishers, Chicago (1976).Google Scholar
  13. 13.
    C. Jacquillat, V. Izrael, M. Weil, C. Chastang, N. Boiron, and J. Bernard, “A study of 120 patients with oligo-blastic leukemia (OBL)” American Association for Cancer Research, Abstract #412, pp 103 (1975).Google Scholar
  14. 14.
    J. R. Cohen, W. P. Creger, P. L. Greenberg and S. L. Schrier, “Subacute myeloid leukemia, a clinical review” The American Journal of Medicine, 66: 959–966 (1979).PubMedCrossRefGoogle Scholar
  15. 15.
    P. L. Greenberg and B. Mara, “The preleukemic syndrome, correlation of in vitro parameters of granulopoiesis with clinical features” The American Journal of Medicine, 66: 51–958 (1979).PubMedCrossRefGoogle Scholar
  16. 16.
    B. Barlogie, G. Spitzer, G. Dosik, D. A. Johnston, K. B. McCredie and E. J. Freireich, “Lithium Carbonate (Li) for the treatment of oligoblastic leukemia” XVII Congress of the International Society of Hematology, Paris, France, (1978).Google Scholar
  17. 17.
    B. Barlogie, D. A. Johnston and L. Smallwood “Clinical evolution of oligoblastic leukemia following lithium carbonate treatment” Submitted to Blood.Google Scholar
  18. 18.
    B. Barlogie, B. Drewinko, G. Dosik and E. J. Freireich, “Cell Kinetics and the management of malignant disease” Acta Pathologica Microbiologica Scandinavia (In press)Google Scholar
  19. 19.
    H. Begemann and W. Hemmerle “Die Mitosetatigkeit des menschlichen Knochenmarks unde ihre Beeinflussung durch cytostatische Substanzen Klin” Wochensehr. 27: 530–537 (1949).CrossRefGoogle Scholar
  20. 20.
    W. Gohde and W. Dittrich “Impulsfluorometrieein neuartiges Durchflussverfahren zur ultraschnellen Mengenbestimmung von ZeiHinhältsstoffen” Acta Histochem. 10: 429–437 (1971).Google Scholar
  21. 21.
    W. Gohde, J. Schuman, T. Buchner, F. Otto and B. Barlogie “Pulse cytophotometry: Its application to tumor cell biology and clinical oncology” in: Flow Cytometry and Sorting, M. R. Melamed, P. F. Mullaney and M.L. Mendelsohn, editors, New York, John Wiley and Sons, Inc., (1979).Google Scholar
  22. 22.
    B. Barlogie, G. Spitzer, J. S. Hart, D. A. Johnston, T. Büchner, J. Schumann and B. Drewinko “DNA-histogram analysis of human hemopoietic cells” Blood 48: 245–258 (1976).PubMedGoogle Scholar
  23. 23.
    B. Barlogie, J. Latreille, C. T. Fu, J. Franco, M. Meistrich, and M. Andreeff, “Characterization of Hematologic Malignancies by Flow Cytometry” Blood Cells (In press).Google Scholar
  24. 24.
    B. Barlogie and B. Drewinko “Cell Cycle stage dependent induction of G2 phase arrest by different antitumor agents” in: Third International Symposium on Pulse Cytophotometry, D. Lutz, editor, European Press Medikon, Gent, Eur, J. of Cancer 14:7 (1978).Google Scholar
  25. 25.
    B. Barlogie, W. Hittelman, G. Spitzer, J. S., Hart, J. M. Trujillo, L. Smallwood and B. Drewinko “Collreation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma” Cancer Res. 37: 4400–4407 (1977).PubMedGoogle Scholar
  26. 26.
    B. Barlogie, W. Gohde, D. A. Johnston, L. Smallwood, J. Schumann, and B. Drewinko, Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res. 38: 3333–3339 (1978).PubMedGoogle Scholar
  27. 27.
    B. Barlogie, B. Drewinko, J. Schumann, W. Ghode, G. Dosik, J. Latreille, D. A. Johnston and E. J. Freireich, “Cellular DNA content as a marker of human neoplasia” The American Journal of Medicine, 69: 196–203 (1980).Google Scholar
  28. 28.
    M. Andreeff, Z. Darzynkiewicz, T. Sharpless, B. Clarkson and M. R. Melamed “Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA” Blood 55: 282–293 (1980).PubMedGoogle Scholar
  29. 29.
    J. Latreille, B. Barlogie, G. Dosik, D. A. Johnston, B. Drewinko and R. Alexanian “Cellular DNA content as a marker of human multiple myeloma” Blood, 55: 403–407 (1980).PubMedGoogle Scholar
  30. 30.
    J. Latreille, B. Maxwell, D. Johnston, J. Franco, B. Barlogie, T. Loo and R. Alexanian “Ploidy analysis of multiple myeloma bone marrow by DNA flow cytometry and mitotic karyotyping” Annual Meeting American Association for Cancer Research, Proceedings Abstract #C-640 (1980).Google Scholar
  31. 31.
    J. Latreille, B. Barlogie, D. A. Johnston, B. Maxwell, B. Drewinko and R. Alexanian “Ploidy and proliferative characteristics in monoclonal gammopathy” Submitted to Blood.Google Scholar
  32. 32.
    J. Latreille, B. Barlogie, R. Lefebvre, R. Alexanian, “Acridine orange flow cytometry of DNA/RNA content multiple myeloma” Submitted Fifth International Symposyum on Flow Cytometry, Rome, Italy (1980).Google Scholar
  33. 33.
    M. L. Mendelsohn “Autoradiographic analysis of cell proliferation in spontaneous breast cancer in C3H mouse. II. Growth and Survival of Cells labelled with Tritiated Thymidine” Journal of National Cancer Institute 25: 45–500 (1960).Google Scholar
  34. 34.
    I. Tannock, “Cell kinetics and chemotherapy; a critical review” Cancer Treatment Rep. 62: 1117–1133 (1978).Google Scholar
  35. 35.
    R. Baserga, W. E. Kisieleski and K. Haldorsen “A study on the establishment and growth of tumor metastates with tritiated thymidine” Cancer Res. 20: 910–917 (1960).PubMedGoogle Scholar
  36. 36.
    B. Drewinko, R. Alexanian, H. Boyer, B. Barlogie and S. I. Rubinow “The growth fraction of human myeloma cells” Blood (In press).Google Scholar
  37. 37.
    J. S. R. Nelson and L. M. Schiffer “Autoradiographic detection of DNA polymerase containing nuclei in sarcoma 180 ascites cells” Cell and Tissue Kinetics 6: 45–54 (1973).PubMedGoogle Scholar
  38. 38.
    Z. Darzynikiewicz, M. Andreef, F. Traganos, T. Sharpless, and M. Melamed “Discrimination of cycling and non-cycling lymphocytes by BU d R-suppressed acridine orange fluorescence in a flow cytometric system” Exp. Cell Res. 115: 31–35 (1978).CrossRefGoogle Scholar
  39. 39.
    P. Rao, B. Wilson and T. Puck “Premature chromosome condensation for cell cycle analysis” Journal Cell Phisiol. 91: 131–142 (1977).CrossRefGoogle Scholar
  40. 40.
    W. Hittleman and P. Rao “Mapping G1 phase by the structural morphology of the prematurely condensed chromosome” Journal of Cell Physiol. 95: 333–342 (1978).CrossRefGoogle Scholar
  41. 41.
    C. Nicolini, S. Ng and R. Baserga “Effect of chromosomal protein extractable with low concentrations of Na Cl on chromatin structure of resting and proliferating cells” Proceedings National Academy of Sciences, USA 72: 2361–2365 (1975).CrossRefGoogle Scholar
  42. 42.
    M. E. Lalande, and R. C. Miller “Fluorescence flow analysis of lymphocytes activation using Hoechst 33342 dye” Journal of Histochem and Cytochem 27: 394–397 (1979).CrossRefGoogle Scholar
  43. 43.
    Z. Darznkiewicz, F. Traganos, M. Andreef, T. Sharpless and M. R. Melamed “Different sensitivity of chromatin to acid denaturation in quiescent and cycling cells revealed by flow cytometry” Journal Histochem and Cytochem 27: 478–485 (1979).CrossRefGoogle Scholar
  44. 44.
    L. Teodori, A. M. Maddox, B. Barlogie, J. J. Stragand “5-Bromodeoxyuridine (BUdR) quenching of acridine orange (AO) in human bone marrow as a potential probe for growth fraction determination rn vitro” Submitted Fifth International Symposium on Flow Cytometry, Rome Italy, (1980).Google Scholar
  45. 45.
    R. M. Bohmer “Flow cytometric cell cycle analysis using the quenching of 33258 Hoechst fluorescence by bromodeoxyuridine incorporation” Cell and Tissue Kinetics 12: 101–110 (1979).PubMedGoogle Scholar
  46. 46.
    O. J. Eigsti and P. Dustin “Colchicine” Iowa State College Press, AMES, Iowa (1955).Google Scholar
  47. 47.
    T. T. Puck and J. Steffin “Life cycle analysis of mammalian cells” Biophys. J. 3: 379–397 (1963).PubMedCrossRefGoogle Scholar
  48. 48.
    E. Frei, III, J. Whang, R. B. Scoggins, E. J. van Scott, D. P. Rail and M. Ben “The stathmokinetic effect of vincristine” Cancer Res. 24: 1918–1925 (1964).Google Scholar
  49. 49.
    G. M. Dosik, B. Barlogie, R. Allen, W. Gohde and B. Drewinko “A rapid automated stathmokinetic method for determination of in vitro cell cycle transit times” Cell and Tissue Kinetics (In press).Google Scholar
  50. 50.
    J. E. Sisken and L. Moraska “Intrapopulation kinetics of the mitotic cycle” Journal. Cell Biol. 25:179–189 (. 1965 ).Google Scholar
  51. 51.
    B. Drewinko, B. Bobo, P. Roper, M. A. Malahy, B. Barlogie and B. Jansson “Analysis of the growth kinetics of a human lymphoma cell line” Cell and Tissue Kinetics 11: 177–191 (1978).PubMedGoogle Scholar
  52. 52.
    D. E. Wimber and H. A. Ouastler, “A 14C- and 3H-thymidine double labelling technique in the study of cell proliferation in Tradescantia, Root Tips” Exp. Cell Res. 30: 8–22 (1963).CrossRefGoogle Scholar
  53. 53.
    S. E. B. Harris and D. Hoelzer “An evaluation of various double labelling and autoradiogrpahic techniques for the measurement of DNA synthesis times in leukemic cells” Journal Microsc. 96: 205–217 (1972).CrossRefGoogle Scholar
  54. 54.
    B. Schultze, W. Maurer and H. Hagenbusch A two emulsion autoradiographic technique and the discrimination of 3 different types of labelling after double-labelling with 3H- and 14C- thymidine. Cell and Tissue Kinetics 9: 245 (1976).Google Scholar
  55. 55.
    J. W. Gray, J. H. Carver, Y. S. George and M. L. Mendelsohn, “Rapid cell cycle analysis by measurements of the radioactivity per cell in a narrow window in S phase (RCS.)” Cell and Tissue Kinetics 10: 97–110 (1977).PubMedGoogle Scholar
  56. 56.
    S. H. Rosenoff, F. Bostik and R. C. Young “Recovery of normal hemopoietic tissue and tumor following chemotherapeutic injury from cytophosphamide (CTX). Comparative analysis of biochemical and clinical techniques” Blood 45: 465 (1975).PubMedGoogle Scholar
  57. 57.
    S. H. Rosenoff, J. M. Bull and R. C. Young “The effects of chemotherapy on the kinetics and proliferative capacity of normal and tumor tissues in vivo” Blood 45: 107–118 (1975).PubMedGoogle Scholar
  58. 58.
    W. R. Vogler, Z. H. Israili, A. G. Zoliman, S. Moffitt and B. Barlogie “Marrow Cell kinetics in patients treated with methotrexate and citrovorum factor” Cancer (In press).Google Scholar
  59. 59.
    S. B. Howell, A. Drishan and E. Frei, III “Cytokinetic comparison of thymidine and leukovorum rescue of marrow in humans after exposure to high-dose methotrexate” Cancer Res. 39: 1315–1320 (1979).PubMedGoogle Scholar
  60. 60.
    T. T. Puck and P. Marcus “A rapid method for viable cells tritration and clone production with He La cells and tissue culture: The use of x-irradiated cells to supply conditioning factors” Proceedings National Academy of Science USA, 41: 432–438 (1955).CrossRefGoogle Scholar
  61. 61.
    A. W. Hamburger and S. E. Salmon “Primary bioassay of human tumor stem cells” Science 197: 461–463 (1977).PubMedCrossRefGoogle Scholar
  62. 62.
    S. E. Salmon, A. W. Hamburger and B. Soehnlen “Quantitation of different sensitivity of human tumor stem cells to anti-cancer drugs” New England Journal of Medicine 298: 1231–1327 (1978).CrossRefGoogle Scholar
  63. 63.
    S. E. Salmon “Human tumor stem cells in adjuvant therapy of cancer” in: Adjuvant therapy of cancer, II, S. E. Jones and S. E. Salmon, editors, Grune and Stratton, Inc. New York, (1979).Google Scholar
  64. 64.
    G. G. Steel “Cell loss from experimental tumor” Cell and Tissue Kinetics 1: 193–207 (1968).Google Scholar
  65. 65.
    D. Price Dynamics of proliferating tissues, University of Chicago Press, Chicago (1958)Google Scholar
  66. 66.
    P. C. Dyke and D. A. Mulkey “Maturation of ganglioneuromastoma to ganglioneurom” Cancer 20: 1343–1349 (1967).PubMedCrossRefGoogle Scholar
  67. 67.
    L. H. Einhorn and J. P. Donohue “Combination chemotherapy in disseminated testicular cancer: The Indiana University Experience” Seminars in Oncol. 6: 87–93 (1979).Google Scholar
  68. 68.
    W. Hittleman, B. Barlogie and F. Davis Unpublished observations.Google Scholar
  69. 69.
    N. Levine and F. L. Meyskens “Topical vitamin-A-acid therapy for cutaneous metastatic melanoma” Lancet 2: 224–226 (1980).PubMedCrossRefGoogle Scholar
  70. 70.
    L. Sachs “Control of normal cell differentiation in leukemic white blood cells” in: Cell differentiation and neoplasia, G. S. Saunders, editor, Raven Press, New York (1978).Google Scholar
  71. 71.
    A. Brugarolas and M. Gosalvez “Treatment of cancer by an inducer of reverse transformation” Lancet 1: 68–70 (1980).PubMedCrossRefGoogle Scholar
  72. 72.
    M. L. Mendelsohn “The growth fraction: A new concept applied to tumors” Science 130: 1496 (1960).Google Scholar
  73. 73.
    R. Kallman, C. Combs, A. Franko, B. Furlong, S. Kelley, H. Kemper, R. Miller, B. Rapacchietta, D. Schoenfeld, and M. Takahashi “Evidence for the recruitment of non-cycling clonogenic tumor cells” in: Radiation Biology in Cancer Res., R. E. Meyn and H. R. Withers, editors, Raven Press, New York, (1980).Google Scholar
  74. 74.
    B. K. Bhuyan, T. J. Fraser and K. J. Day “Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultures L1210 cells” Cancer Res., 37: 1057–1063 (1977).PubMedGoogle Scholar
  75. 75.
    B. Drewinko, M. Patchen, L. Y. Yang and B. Barlogie “Differential killing efficacy of 20 antitumor drugs on proliferating and non-proliferating human tumor cells” Cancer Res. (In press).Google Scholar
  76. 76.
    B. Barlogie, P. M. Corry and B. Drewinko “In vitro thermochemotherapy of human colon cancer cells with cis-platinum and multomycin-C” Cancer Res. 40: 1165–1168 (1980).PubMedGoogle Scholar
  77. 77.
    W. R. Bruce, B. E. Meeker and F. A. Valeriote “Comparison of the sensitivity of normal hemopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo” Journal of the National Cancer Institute 37; 233–245 (1966).PubMedGoogle Scholar
  78. 78.
    F. Mauro and H. Madoc-Jones “Age responses of cultured mammalian cells to cytotoxic agents” Cancer Res. 30: 1397–1408 (1970).PubMedGoogle Scholar
  79. 79.
    B. Barlogie and B. Drewinko “Cell cycle related induction of cell progression delay” 29th Annual Symposium on Fundamental Cancer Research, Houston, TX March 10–12, 1976.Google Scholar
  80. 80.
    L. K. Persohn, B. Drewinko and T. L. Loo “Uptake of 1-ß-Darabinofuranosyl cytosine by synchronized human lymphoma cells” Med. Pediatric Oncology, 2: 291–297 (1976).CrossRefGoogle Scholar
  81. 81.
    S. S. Ford and S. E. Shackney “Lethal and sublethal effects of hydroxyurea in relation to drug concentration and duration of drug exposure in sarcoma 180 in vitro” Cancer Res. 37: 2628–2637 (1977).PubMedGoogle Scholar
  82. 82.
    S. E. Shackney, B. W. Erickson and C. E. Lengel “Schedule optimization of cytosine arabinoside (CA) in hydroxyurea (HU) in sarcoma 180 in vitro” AACR Abstract #900 (1978).Google Scholar
  83. 83.
    M. Raber, B. Barlogie, H. Pritsche and C. Bedrossian “Cytokinetic, cytogenetic and hormonal assessment of human breast cancer” American Association for Cancer Research, Proceedings Abstract #348, May (1980).Google Scholar
  84. 84.
    L. M. Schiffer, P. G. Braunschweiger, J. J. Stradand and L. Poulakoa “The cell kinetics of human mammary cancers” Cancer 43: 1707–1719 (1979).PubMedCrossRefGoogle Scholar
  85. 85.
    G. L. Wantzen, H. Karle and S. A. Killman “Nuclear DNA polymerase estimation in human keukemic meyloblasts” British Journal of Hematology 33: 329–334 (1976).CrossRefGoogle Scholar
  86. 86.
    D. E. Swartzendruber, K. Z. Cox and M. E. Wilder “Flow cytoenzymology of the early differentiation of mouse embryonal carcinoma cells” Differentiation 16: 23–39 (1980).PubMedCrossRefGoogle Scholar
  87. 87.
    H. E. Broxmeier, N. Jacobson, J. Kurland, H. Mendelsohn and M. A. Moore “In vitro suppression of normal granulocytic stem cells by inhibitory activity derived from human leukemia cells” J. National Cancer Institute 60: 497–511 (1978).Google Scholar
  88. 88.
    B. C. Lampkin, T. Nagao and A. M. Mauer “Synchronization and recruitment in acute leukemia” J. Clin. Invest. 50: 2204–2214 (1971).PubMedCrossRefGoogle Scholar
  89. 89.
    F. A. Hayes, A. A. Green and A. M. Mauer “Correlation of cell kinetics and clinical response in chemotherapy in disseminated neuroblastoma” Cancer Res. 37: 3766–3770 (1977).PubMedGoogle Scholar
  90. 90.
    P. J. Burke, J. E. Karpe, H. G. Braine and W. P. Vaughan “Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors” Cancer Res. 37: 2138–2146 (1977).PubMedGoogle Scholar
  91. 91.
    P. J. Burke, Personal communication.Google Scholar
  92. 92.
    L. M. van Putten “Are cell kinetics relevant for the design of tumor chemotherapy schedules?” Cell and Tissue Kinetics 7: 493–504 (1974).PubMedGoogle Scholar
  93. 93.
    B. Barlogie and B. Drewinko “Lethal and kinetic response of cultured human lymphoid cells to melphalan” Cancer Treatment Rep. 61: 415–436 (1977).Google Scholar
  94. 94.
    B. Barlogie, B, Drewinko, W. Gohde and G. P. Bodey “Lethal and kinetic effects of peptichemio on cultured human lymphoma cells” Cancer Res. 37: 2583–2588 (1977).Google Scholar
  95. 95.
    W. Gohde, M. Meistrich, R. Meyn, J. Schumann and B. Barlogie “Cell cycle phase dependence of drug induced cycle progression delay” J. Histochem. Cytochem. 27: 470–473 (1979).PubMedCrossRefGoogle Scholar
  96. 96.
    B. Barlogie, T. Buchner, U. Asseburg, D. Kamanabroo “Zellkinetischer effekt von cytosin-arabinoside im klinischen test” Med. Welt. 25: 1532 (1974).PubMedGoogle Scholar
  97. 97.
    B. Barlogie, W. Plunkett, M. Rabert, J. Latreille, M. Keating and K. McCredie In vivo cellular kinetics and pharmacology studies of Ara-C and 3-DAU chemotherapy for relapsing acute leukemia. Cancer Res. (In press).Google Scholar
  98. 98.
    H. T. Rupniak and D. Paul “Selective killing of transformed cells by exploitation of their defective cell cycle control by polyamines” Cancer Res. 40: 293–297 (1980).PubMedGoogle Scholar
  99. 99.
    G. M. Kosik, B. Barlogie, D. A. Johnston, W. K. Murphy and B. Drewinko “Lethal and cytokinetic effects of anguidine on a human colon cancer cell line” Cancer Res. 38: 3304–3309 (1978).Google Scholar
  100. 100.
    L. Reodori, C. T. Fu and B. Barlogie “In vitro cell cycle and lethal effects of anguidine” Cell Kinetics Society, Abstract #48 (1980).Google Scholar
  101. 101.
    L. Teodori, B. Barlogie, B. Drewinko, D. Swartzendruber and F. Mauro “Reduction of Ara-C and adriamycin cytotoxicity following cell cycle arrest b y anguidine” Submitted to Cancer Res.Google Scholar
  102. 102.
    P. C. Raich “Prediction of therapeutic response in acute leukemia” Lancet 1: 74–76 (1978).PubMedCrossRefGoogle Scholar
  103. 103.
    W. Hittleman and P. Rao “The nature of adriamycin-induced cytotoxicity in chinest hamster ovary cells as revealed by premature chromosome condensation” Cancer Res. 35: 3027–3030 (1975).Google Scholar
  104. 104.
    M. Haq, J. Latreilles M. Keating and B. Barlogie “In vivo cell cycle effect of AMSA in relapsing adult acute leukemia” Cell Kinetics Society, Abstract #51 (1980).Google Scholar
  105. 105.
    R. N. Buick and E. A. McCullouch “A clonogenic assay for leukemic blast cells used to measure anthracycline sensitivity in culture” Proceeding AACR, Abstract #360 (1978).Google Scholar
  106. 106.
    R. M. Buick, H. A. Messner, J. E. Till and E. A. McCullouch “Cytotoxicity of adriamycin and daunorubicin for normal and keukemia progenitor cells of man” Journal of National Cancer Institute 62: 249–255 (1979).Google Scholar
  107. 107.
    C. H. Parks, M. Amare, M. A. Savin, J. W. Goodwin, M. M. Newcomb and B. Hoogstraten “Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells” Blood 41: 595–601 (1980).Google Scholar
  108. 108.
    M. J. Cline and E. Rosenbaum “Prediction of in vivo cytotoxicity of chemotherapeutic agents by their effects on leukocytes from patients with acute leukemia” Cancer Res. 28: 2516–2521 (1968).PubMedGoogle Scholar
  109. 109.
    J. E. Byfield and J. J. Stein “A simple radiochemical assay of inhibition by chemotherapeutic agents of precursor incorporation into biopsy samples, effusion and leukocyte preparations” Cancer Res. 28: 2228–2231 (1968).PubMedGoogle Scholar
  110. 110.
    P. C. Raich “Prediction of therapeutic response in acute leukemia” Lancet 1: 74–76 (1978).PubMedCrossRefGoogle Scholar
  111. 111.
    G. M. Dosik, B. Barlogie, D. A. Johnston, D. Mellard and E. J. Freireich “In vitro drug sensitivity test to predict clinical response in acute myeloblastic leukemia” European Journal of Cancer (In press).Google Scholar
  112. 112.
    M. Haq, B. Barlogie, G. M. Dosik, K. McCredie and M. Keating “In vitro drug-induced deoxyribonucleic acid (DNA) synthesis inhibition as a predictive test for clinical response in acute leukemia” The American Society of Clinical Oncology C-459 (1980).Google Scholar
  113. 113.
    F. Traganos, Z. Darzynkiewicz, T. Sharpless and M. R. Melamed: “Simultaneous staining of ribonucleic and deoxyribonucleic acids in unfixed cells using acirdine orange in a flow cytofluorometric system” J. Histochem. Cytochem. 25: 46 (1977).PubMedCrossRefGoogle Scholar
  114. 114.
    A. M. Kshirsayer, in: Multivariate Analysis, New York, Marcel Dekker (1972).Google Scholar
  115. 115.
    Nicolini, C., Parodi, S., Lessin, S., Belmont, A., Abraham, S., Zietz, S., and Grattorola, M. (1979); Chromatin study in situ, II. Static and flow microfluorometry. In: Chromatin Structure and Function, edited by C. Nicolini, pp. 293–323. Plenum Press, New York.CrossRefGoogle Scholar
  116. 116.
    Nicolini, C., Desaive, C., Kendall, F.M., and Giaretti, W. (1977) The G0–G1 transition of WI-38 cells. II. Geometric and densitometric texture analysis. Exp. Cell Res., 106: 118–127.Google Scholar
  117. 117.
    Nicolini, C., Linden, W.A., Zietz, S., and Wu, C.T. (1977): Objective identification of non-proliferating cells in a melanoma B16 tumor in vivo. Nature, 270: 163–176.CrossRefGoogle Scholar
  118. 118.
    Abraham, S., Lessin, S., Vondérheid, EO and C. Nicolini. “Reversible (G0) and irreversible (Q) non cycling cells in human peripheral blood: immunological, biological and structural characterization”. Cell Biophysics, 1981, 2, 4.Google Scholar
  119. 119.
    Nicolini, C., Parodi, S., Belmont, A., Abraham, S., and Lessin, S., (1979): Mass action and acridine orange staining. J. Histochem. Cytochem. 27: 102–113.PubMedCrossRefGoogle Scholar
  120. 120.
    M. Grattarola, S. Zietz, S. Lessin, C. Desaive and C. Nicolini, Early Detection of Micrometastases Via Flow Microfluorimetry, Cancer Biochem, Biophys., (1979), Volo 4, pp. 13–18.Google Scholar
  121. 121.
    C. Nicolini, FMF Analysis of the Cell Cycle: Membrane and Nucleic Acid Stainings, Advances in Neuroblastoma Research edited by Audrey E. Evans. Raven Press, New York (c) 1980. 271–286.Google Scholar
  122. 122.
    Lessin, S., Abraham, S., and Nicolini, C. (1981): “High versus low metastatic potential melanoma cells: biophysical cytological studies.”Histochemical Journal.Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Barthel Barlogie
    • 1
  • Benjamin Drewinko
    • 1
  • Martin N. Raber
    • 1
  • Douglas E. Swartzendruber
    • 1
  1. 1.The University of Texas System Cancer CenterM.D. Anderson Hospital and Tumor InstituteHoustonUSA

Personalised recommendations